Allarity Therapeutics received a Notice of Allowance from the U.S. Patent and Trademark Office on April 27 2026 for its Drug Response Predictor (DRP) companion diagnostic that accompanies the company’s dual PARP/tankyrase inhibitor, stenoparib. The allowance covers multiple claims and is expected to be formally granted within three months, giving Allarity exclusive rights to the diagnostic in the United States through at least 2039.
The approval strengthens Allarity’s intellectual‑property position by protecting the technology that identifies patients most likely to benefit from stenoparib. By extending exclusivity, the patent allows the company to potentially capture a larger share of the platinum‑resistant ovarian cancer market and to negotiate more favorable commercial agreements with partners. The long‑term exclusivity period is a key competitive advantage for a single‑asset oncology company.
The DRP platform has been validated in more than 35 clinical studies and demonstrates high predictive accuracy for patient responders. It is integral to stenoparib’s development program, which has received Fast Track designation from the FDA for advanced ovarian cancer. The diagnostic’s ability to select patients is expected to accelerate regulatory submissions and market entry.
Allarity recently secured a $20 million non‑convertible debt financing deal with Streeterville Capital, extending its cash runway into mid‑2028. While the company’s Altman Z‑score signals financial distress and a high probability of bankruptcy within two years, the new IP milestone may improve investor confidence and support future funding efforts.
Shares of Allarity rose 7.2% over the past week, a move that analysts attribute to the patent allowance’s long‑term exclusivity and the company’s strategy of combining precision diagnostics with a novel therapeutic.
Thomas Jensen, CEO, said, "This Notice of Allowance from the USPTO represents another successful milestone in our efforts to secure intellectual property protection for our DRP® technology in the US, the world's most important pharmaceutical market. Critically, this patent maximizes the marketing exclusivity in the US for stenoparib in patients selected using the stenoparib DRP test, which is especially important as we seek to accelerate stenoparib toward approval for Ovarian and other cancers."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.